Propanc Biopharma highlights PRP preclinical pancreatic cancer results

Propanc Biopharma says its PRP preclinical PDAC package showed >90% tumor-growth inhibition and a >2.5-fold survival benefit, and contrasts PRP versus Erasca’s Phase 1 ERAS-0015 dataset.